William J. Grist, MD

LICENSES/CERTIFICATIONS:

American Board of Otolaryngology - 1981

State of Georgia Medical License - issued 1978

APPOINTMENTS:

Emory University Hospital
Chief
Department of Otolaryngology - Head and Neck Surgery
1995 - present

Emory University School of Medicine
Associate Professor
Department of Otolaryngology - Head and Neck Surgery
1992 - present

Veteran Administration Medical Center, Decatur, GA
Chief
Otolaryngology Service
1986 - present

Emory University School of Medicine
Interim Chief
Department of Otolaryngology - Head and Neck Surgery
1996-1998

Emory University School of Medicine
Associate Professor
Department of Surgery
1992

Emory University School of Medicine
Assistant Professor
Department of Surgery
1982-1992

Emory University School of Medicine
Instructor
Department of Surgery
1981-1983

HONORS AND AWARDS:

Alpha Omega Alpha
Medical Honor Society

PROFESSIONAL MEMBERSHIPS:

American Academy of Otolaryngology - Head and Neck Surgery

American Medical Society

American Academy of Facial Plastic and Reconstructive Surgery

American College of Surgeons

Greater Atlanta Otolaryngology Society
President Elect, 2002-2003
President, 1993-1994
President Elect, 1992-1993
Secretary, 1991-1992
Treasurer, 1990-1991

Georgia Society of Otolaryngology
President, 2003 - present

Medical Association of Georgia

RECENT PUBLICATIONS:

Sharara N, Muller S, Olson J, Grist WJ, Grossniklaus HE. Sinonasal undifferentiated carcinoma with orbital invasion. Ophthalmic, Plastic and Reconstructive Surgery. 2001;14(4):288-292.

Seyer BA, Grist W, Muller S. Aggressive destructive midfacial lesion from cocaine abuse. Oral Surg Oral Med Oral Pathol. 2002; 94:465.

TOPICS OF RESEARCH:

An investigation of the hemostatic properties of J-coll, a new hemostatic agent (sponsored by Johnson & Johnson)
Controlled, double-blind, randomized, multi-center clinical trial comparison of the safety and efficacy of ciprofloxacin vs. clarithromycin in the treatment of patients with acute sinusitis (sponsord by Miles, Inc.)
A multicenter, multi-national, ope label, single group, single and multiple dose study of foscan-mediated photodynamic therapy (PDT) for the palliative treatment of current, refractory or second primary squamous cell carcinoma of th ehead and neck in patients considered to be incurable with surgery or radiotherapy (sponsored by Scotia Pharmaceuticals, Ltd., Quintiles Oncology Division)